JCM Figure table search 04
Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Hahn, R. C.
Right arrow Articles by Hamdan, J. S.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Hahn, R. C.
Right arrow Articles by Hamdan, J. S.

 Previous Article  |  Next Article 

Journal of Clinical Microbiology, August 2002, p. 2828-2831, Vol. 40, No. 8
0095-1137/02/$04.00+0     DOI: 10.1128/JCM.40.8.2828-2831.2002
Copyright © 2002, American Society for Microbiology. All Rights Reserved.

In Vitro Comparison of Activities of Terbinafine and Itraconazole against Paracoccidioides brasiliensis

R. C. Hahn,1 C. J. F. Fontes,2 R. D. Batista,1 and J. S. Hamdan1*

Department of Microbiology, Biological Sciences Institute, Federal University of Minas Gerais, Belo Horizonte, Minas Gerais,1 Núcleo de Estudos de Doenças Infecciosas e Tropicais, TRÓPICA, Faculdade de Ciências Médicas, Universidade Federal de Mato Grosso, Cuiaba, Mato Grosso, Brazil2

Received 24 July 2001/ Returned for modification 24 December 2001/ Accepted 8 May 2002


   ABSTRACT
Top
 Abstract
Introduction
 Materials and Methods
 Results and Discussion
 References
 
In vitro, terbinafine is highly active against a broad spectrum of pathogenic fungi. We evaluated the activities of terbinafine and itraconazole against 31 isolates of Paracoccidioides brasiliensis. The tests were conducted by using a broth macrodilution procedure. MICs, in micrograms per milliliter, were as follows: terbinafine, 0.015 to 1.0 (geometric mean, 0.1188); itraconazole, 0.007 to 0.5 (geometric mean, 0.03165). The usual therapy for paracoccidioidomycosis is sulfonamides, amphotericin B, and azole derivatives (ketoconazole, itraconazole, and fluconazole). In comparison to amphotericin B, azole derivatives allow shorter treatment courses, can be administered orally, and are equally effective. Itraconazole has as high efficacy as ketoconazole, but with superior tolerance. It is the current drug of choice for treatment of paracoccidioidomycosis. The data obtained in this study indicate that terbinafine is active against P. brasiliensis in vitro and suggest that this allylamine can be considered a new option as drug therapy for paracoccidioidomycosis.


   INTRODUCTION
Top
 Abstract
 Introduction
Materials and Methods
 Results and Discussion
 References
 
Paracoccidioidomycosis, caused by the dimorphic fungus Paracoccidioides brasiliensis, is a systemic human mycosis geographically confined to Latin America (1, 25, 28). In vitro tests of the susceptibility of P. brasiliensis to antimycotic drugs have been scarce, and the results have not always been consistent; the discrepancies are attributed to the diversity of techniques employed in such studies (7, 8,10, 11, 22, 28).

Organisms belonging to the kingdom Fungi share eukaryotic characteristics with their human host cells, implying similarities in biochemistry and physiology that limit therapeutics. Therefore, when systemic administration of drugs is required for deep human mycoses, few compounds are sufficiently selective (12). Compounds currently used in the control of infection caused by P. brasiliensis include amphotericin B, trimethoprim-sulfamethoxazole, and azole derivatives (26). Unfortunately, amphotericin B has been associated with substantial toxicity, while trimethoprim-sulfamethoxazole has been associated with relapses. Thus, in many clinical situations, the azole derivatives present the best therapeutic option for control of paracoccidioidomycosis (17, 18).

Owing to the fact that itraconazole, among the azoles, permits shorter treatment courses and has been shown to be more effective, we decided to compare this drug with the antifungal agent terbinafine, which operates by interfering with the ergosterol biosynthetic pathway and has shown MICs similar to those of itraconazole for filamentous fungi in in vitro studies (10, 15). Thus, we aim to determine whether terbinafine might have a role in the management of infections caused by P. brasiliensis.


   MATERIALS AND METHODS
Top
 Abstract
 Introduction
 Materials and Methods
Results and Discussion
 References
 
Fungal strains and culture conditions. Thirty-one isolates of the P. brasiliensis yeast form, including clinical, environmental, and animal isolates, were examined in this study. Samples consisted of 28 strains isolated from humans, 1 from penguin feces, 1 from dog food, and 1 from an armadillo. Quality control isolates included Pb-JT-1 (ATCC 90659), Pb-9 (ATCC 36324), and Pb-73 (ATCC 32071). The following characteristics of the isolates are given in Table 1: date of sampling, geographic location, and, when isolates originated from a human source, the clinical form and manifestation, type and location of lesions, and the patient's sex, age, and occupation. Isolates were adapted to a McVeigh-Morton (MVM) chemically defined culture medium with a pH of 7.0 (24), and yeast cells in the exponential phase of growth were obtained by transports at 5- to 7-day intervals and incubation at 35°C (7, 24). The strains are maintained at the Mycology Laboratory, Federal University of Minas Gerais, Belo Horizonte, Minas Gerais, Brazil, in Fava-Netto solid medium (5) by means of subculture at 30- to 40-day intervals and incubation at 35°C.


View this table:
[in this window]
[in a new window]
  		TABLE 1. P. brasiliensis isolates

 
Susceptibility testing. (i) Antifungal agents. The azole derivative used in this study was itraconazole (Janssen, Beerse, Belgium). Terbinafine was obtained from the Novartis Research Institute (Vienna, Austria). These drugs were obtained from their manufacturers as standard powders, each from a single lot.

(ii) Determination of MICs. The MICs of itraconazole and terbinafine for each strain were determined by using a broth macrodilution procedure according to the work of Shadomy et al. (30).

Stock solutions of itraconazole (1 mg/ml) were freshly prepared in dimethyl sulfoxide (DMSO). Serial twofold dilutions of itraconazole were made by using MVM medium as the diluent to yield final drug concentrations ranging from 4 to 0.007 µg/ml (6). For terbinafine, stock solutions were also freshly prepared in DMSO and further diluted in sterile MVM medium as necessary. A twofold dilution series ranging from 32 to 0.015 µg/ml was employed (16). Drug-free and titrated solubilizing vehicle (DMSO) controls were included. Inocula were determined spectrophotometrically by using a yeast phase suspension in sterile 0.85% saline that gave 69 to 70% transmittance at 520 nm. The inoculum was quantified by yeast cell counts. Yeast cells were collected from the solid medium (MVM) and diluted (1:10) in a counting solution containing 0.9% NaCl, 4% formaldehyde, and 4% Tween 20. The mixture was vortexed to disperse aggregated cells. Counting was performed in a Neubauer chamber. An initial inoculum density of 105 cells/ml was obtained (22).

A 0.1-ml aliquot of this suspension was then added to 0.9 ml of MVM broth containing the desired dilution of the drug, giving a final concentration of approximately 104 cells/ml (4, 6,22). Strains were grown at 35°C under agitation in a shaker. MICs of itraconazole and terbinafine were defined as the lowest concentration that resulted in a visual turbidity corresponding to 80% inhibition compared with the turbidity produced by the growth control (6). Since there is no established standard for a terbinafine end point, we arbitrarily selected 80% inhibition as the end point for this antifungal agent in our study (14).


   RESULTS AND DISCUSSION
Top
 Abstract
 Introduction
 Materials and Methods
 Results and Discussion
References
 
The MIC50 and MIC90 (MICs at which 50 and 90% of isolates are inhibited, respectively) of both antifungal drugs were determined for all 31 P. brasiliensis isolates (Table 2). The geometric mean MIC of itraconazole was 0.03165 mg/ml, and that of terbinafine was 0.1188 mg/ml.


View this table:
[in this window]
[in a new window]
  		TABLE 2. In vitro comparison of itraconazole and terbinafine MICs

 
In vitro susceptibilities of P. brasiliensis to antifungal drugs have been determined by several investigators (7, 8,11, 14, 23, 29). Some of these previous studies (8, 14, 29) compared susceptibilities in the yeast phase and the mycelial phase of P. brasiliensis, finding small differences that were attributed to variations in the lipid composition of the two morphological phases. In the present study we have worked with the yeast form of P. brasiliensis for the principal reason that this is the parasitic fungal phase and therefore the target of whatever drug is intended to benefit the human host. Naturally, our results can be compared only with those obtained by other authors with reference to the yeast phase of P. brasiliensis.

Our MIC data for itraconazole are similar to those reported by others (8, 29), which collectively show that this fungus is extremely sensitive to this drug. No significant difference was observed between the MICs obtained for isolates from patients and those obtained for environmental isolates: Pb-262 (isolated from dry dog food in Minas Gerais, Brazil), Pb-Pinguim (isolated from penguin feces from the Uruguayan Antarctic), and Pb-Tatu (isolated from the intestines of an armadillo captured in the region of Pará, Brazil).

In spite of the facts that itraconazole is currently considered the drug of choice for treatment of paracoccidioidomycosis and that a series of studies have shown its efficacy in clinical cases (17, 18, 31), it is not yet possible to correlate in absolute terms the antifungal activities of the drug in vitro and in vivo. This is principally because of the lack of standardized methodology to determine MICs for dimorphic fungi and the lack of studies that show a parallel between the MIC determined in vitro and therapeutic results obtained during the course of the disease.

Many investigators have used different techniques to determine the MIC. The only standardization for this procedure is the reference method of the NCCLS, adapted primarily for yeasts (19). Nonetheless, this methodology, already in its third version, has not yet been established as the final standard for dimorphic fungi.

In the present study macrodilution in a synthetic medium and preparation of inocula by spectrophotometry were used as proposed by NCCLS M38-P. In both methods the physiological requirements of each tested microorganism are considered in order to allow adequate reading time. Furthermore, the MICs of the azoles in both methods are defined as the lowest concentration resulting in a visual turbidity corresponding to >=80% inhibition compared with the turbidity of the growth control tube. The MIC for terbinafine was defined as the lowest drug concentration inhibiting 80% of fungal growth, as determined by comparison (as above) to the growth control.

The main differences between the methodology presented here and the modified NCCLS method used in the study by McGinnis et al. with P. brasiliensis (14) are the phase of the inoculum (104 cells from the mycelial phase in the study by McGinnis et al. as opposed to 104 cells of the yeast phase in our study) and the composition of the synthetic medium, including changes in the glucose concentration (0.2% in RPMI 1640 and 1% in MVM medium, respectively). Martinez-Suarez and Rodriguez-Tudela (13) have reported that addition of as much as 2% glucose to culture media helps in the reading of MICs of azole compounds. According to Espinel-Ingroff et al. (3), addition of 2% glucose to RPMI 1640 medium helped in the examination of MIC end points. Perhaps this modification can contribute to the standardization of an adequate methodology for determination of MICs for the study of dimorphic fungi.

The MIC data for terbinafine are homogeneous and low for the isolates tested. Our data agree with the findings of earlier workers who reported that terbinafine has significant antifungal activity against a broad spectrum of fungal organisms (9, 15), including a wide range of filamentous and dimorphic fungi (27).

Because of the variety of test methods employed in these studies, it is difficult to assess the potential clinical relevance of the data. On the other hand, a number of case reports have been published providing MIC data for isolates from various fungal infections successfully treated with terbinafine. These results indicate that favorable in vitro MICs were indeed predictive of clinical success with terbinafine, but of course more data would be required in order to draw any general conclusions (27).

In this study, we demonstrated that terbinafine has potent antifungal activity against P. brasiliensis in vitro. Recently, Ollague et al. (20) published a case study of paracoccidioidomycosis successfully treated with terbinafine. If this is confirmed, it will be the first successful treatment of a systemic fungal infection with terbinafine registered in the literature. To date, the promising activity of this drug against dimorphic pathogens has been confirmed clinically only in the case of sporotrichosis (2, 21). Perhaps now its efficacy may be extended to paracoccidioidomycosis.


   ACKNOWLEDGMENTS
 
We are grateful to Gioconda San-Blás (IVIC, Caracas, Venezuela) for providing strains ATCC 32071, ATCC 36324, Pb-306, and Pb-333 and to Patrícia Cisalpino (UFMG, Belo Horizonte, Brazil) for providing strains Pb-Tatu and Pb-262. We also thank the Novartis Research Institute (terbinafine) and Janssen Pharmaceutical (itraconazole) for providing us with the drugs as standard powders.

This research was supported by the Coordenação de Aperfeiçoamento de Pessoal de Nível Superior (CAPES), Conselho Nacional de Desenvolvimento Científico e Tecnológico (CNPq), and Fundação de Amparo à Pesquisa do Estado de Minas Gerais (FAPEMIG).


   FOOTNOTES
 
* Corresponding author. Mailing address: Departamento de Microbiologia, ICB/UFMG, Av. Antônio Carlos, 6627, 31270-901 Belo Horizonte, Minas Gerais, Brazil. Phone: 55 31 3499-2758. Fax: 55 31 3499-2730. E-mail: handan{at}icb.ufmg.br. Back


   REFERENCES
Top
 Abstract
 Introduction
 Materials and Methods
 Results and Discussion
 References
 

  1. Brummer, E., E. Castañeda, and A. Restrepo. 1993. Paracoccidioidomycosis: an update. Clin. Microbiol. Rev. 6:89-117.[Abstract/Free Full Text]
  2. Ellis, D. H. 1998. The potential for terbinafine in non-dermatophyte fungal infections with or without skin involvement. J. Dermatol. Treat. 9(Suppl. 1):S35-S38.
  3. Espinel-Ingroff, A., M. Pfaller, M. E. Erwin, and R. N. Jones. 1996. Interlaboratory evaluation of Etest method for testing antifungal susceptibilities of pathogenic yeasts to five antifungal agents by using Casitone agar and solidified RPMI 1640 medium with 2% glucose. J. Clin. Microbiol. 34:848-852.[Abstract]
  4. Espinel-Ingroff, A., T. M. Kerkering, P. R. Goldson, and S. Shadomy. 1991. Comparison study of broth macrodilution and microdilution antifungal susceptibility tests. J. Clin. Microbiol. 29:1089-1094.[Abstract/Free Full Text]
  5. Fava Netto, C. 1955. Estudos quantitativos sobre a fixação do complemento na blastomicose Sul Americana com antígeno polissacarídico. Arq. Cir. Clin. Exp. 18:197-254.
  6. Hahn, R. C., and J. S. Hamdan. 2000. In vitro susceptibilities of Pararacoccidioides brasiliensis yeast form to antifungal drugs. Mycoses 43:403-407.[CrossRef][Medline]
  7. Hamdan, J. S., and M. A. Resende. 1988. Lipid composition and effect of amphotericin B on yeast cells of Paracoccidioides brasiliensis. Mycopathologia 102:97-105.[CrossRef][Medline]
  8. Heins-Vaccari, E. M., N. T. Melo, C. S. Lacaz, A. D. Pereira, and G. Del Negro. 1988. Ação in vitro do itraconazol (R-51211) sobre Paracoccidioides brasiliensis, Histoplasma capsulatum var. capsulatum e Histoplasma capsulatum var. duboisii. An. Bras. Dermat. 63:299-302.
  9. Jessup, C. J., N. S. Ryder, and M. A. Ghannoum. 2000. An evaluation of the in vitro activity of terbinafine. Med. Mycol. 38:155-159.[Medline]
  10. Jesuino, R. S. A., R. B. A. Soares, S. M. Salem-Izaac, M. Pereira, M. S. S. Felipe, and C. M. A. Soares. 1997. In vitro amphotericin B effects on growth, viability and dimorphism of Paracoccidioides brasiliensis: reversal of the treatment. Microbiol. Immunol. 41:93-99.[Medline]
  11. Lacaz, C. S., C. M. Ulson, and S. A. P. Sampaio. 1959. Ação in vitro da anfotericina B sobre o P. brasiliensis. Rev. Paul. Med. 54:357-360.
  12. Lyman, C. A., and T. J. Walsh. 1992. Systemically administered antifungal agents. A review of their clinical pharmacology and therapeutic applications. Drugs 44:9-35.[Medline]
  13. Martinez-Suarez, J. V., and J. L. Rodriguez-Tudela. 1995. Patterns of in vitro activity of itraconazole and imidazole antifungal agents against Candida albicans with decreased susceptibility to fluconazole from Spain. Antimicrob. Agents Chemother. 39:1512-1516.[Abstract]
  14. McGinnis, M. R., L. Pasarell, D. A. Sutton, A. W. Fothergill, C. R. Cooper, and M. G. Rinaldi. 1997. In vitro evaluation of voriconazole against some clinically important fungi. Antimicrob. Agents Chemother. 41:1832-1834.[Abstract]
  15. McGinnis, M. R., and L. Pasarell. 1998. In vitro testing of susceptibilities of filamentous ascomycetes to voriconazole, itraconazole, and amphotericin B, with consideration of phylogenetic implications. J. Clin. Microbiol. 36:2353-2355.[Abstract/Free Full Text]
  16. McGinnis, M. R., and L. Pasarell. 1998. In vitro evaluation of terbinafine and itraconazole against dematiaceous fungi. Med. Mycol. 36:243-246.[CrossRef][Medline]
  17. Mendes, R. P., R. Negroni, and A. Arechavala. 1994. Treatment and control of cure, p. 373-387. In M. Franco, C. S. Lacaz, A. Restrepo-Moreno, and G. Del Negro (ed.), Paracoccidioidomycosis. CRC Press, Boca Raton, Fla.
  18. Naranjo, M. S., M. Trujillo, P. Munera, I. Gomez, and A. Restrepo. 1990. Treatment of paracoccidioidomycosis with itraconazole. J. Med. Vet. Mycol. 28:67-76.[Medline]
  19. National Committee for Clinical Laboratory Standards. 1997. Reference method for broth dilution antifungal susceptibility testing of yeasts. Standard M 27-A. National Committee for Clinical Laboratory Standards, Wayne, Pa.
  20. Ollague, J. M., A. M. De Zurita, and G. Calero. 2000. Paracoccidioidomycosis (South American blastomycosis) successfully treated with terbinafine: first case report. Br. J. Dermatol. 143:188-191.[CrossRef][Medline]
  21. Perez, A. 1999. Terbinafine: broad new spectrum of indications in several subcutaneous and systemic mycoses and parasitic diseases. Mycoses 42:150-151.
  22. Pfaller, M. A., M. G. Rinaldi, J. N. Galgiani, M. S. Bartlett, B. A. Body, A. Espinel-Ingroff, R. A. Fromtling, G. S. Hall, C. E. Hughes, F. C. Odds, and A. M. Sugar. 1990. Collaborative investigation of variables in susceptibility testing of yeasts. Antimicrob. Agents Chemother. 34:1648-1654.[Abstract/Free Full Text]
  23. Restrepo, A., and M. A. Tabares. 1984. In vitro susceptibility of Paracoccidioides brasiliensis yeast form to antifungal agents. Rev. Inst. Med. Trop. São Paulo 26:322-328.[Medline]
  24. Restrepo, A. M., and B. E. Jimenez. 1980. Growth of Paracoccidioides brasiliensis yeast phase on a chemically defined culture medium. J. Clin. Microbiol. 12:279-281.[Abstract/Free Full Text]
  25. Rippon, J. W. 1988. Paracoccidioidomycosis, p. 506-531. In J. W. Rippon (ed.), Medical mycology. The pathogenic fungi and the pathogenic actinomycetes, 3rd ed. W. B. Saunders Company, Philadelphia, Pa.
  26. Rivitti, E. A., and V. Aoki. 1999. Deep fungal infections in tropical countries. Clin. Dermatol. 17:171-190.[CrossRef][Medline]
  27. Ryder, N. S. 1999. Activity of terbinafine against serious fungal pathogens. Mycoses 42:115-119.
  28. San-Blás, G. 1993. Paracoccidioidomycosis and its etiologic agent: Paracoccidioides brasiliensis. J. Med. Vet. Mycol. 31:99-113.[Medline]
  29. San-Blás, G., A. M. Calcagnom, and F. San-Blás. 1993. A preliminary study of in vitro antibiotic activity of saperconazole and other azoles on Paracoccidioides brasiliensis. J. Med. Vet. Mycol. 31:169-174.[Medline]
  30. Shadomy, S., A. Espinel-Ingroff, and R. Y. Cartwright. 1987. Estudios de laboratório com agents antifungicos: pruebas de susceptibilidade y bioensayos, p. 1229-1238. In E. H. Lenette, A. Balows, W. J. Hausler, and H. J. Shadomy (ed.), Manual de Microbiologia Clínica, 4th ed. Editorial Medica Panamericana, Buenos Aires, Argentina.
  31. Tobon, A. M., I. Gomez, L. Franco, and A. Restrepo. 1985. Seguimiento post-terapia en pacientes com Paracoccidioidomicosis tratados con itraconazol. Rev. Colomb. Pneumol. 7:74-78.

Journal of Clinical Microbiology, August 2002, p. 2828-2831, Vol. 40, No. 8
0095-1137/02/$04.00+0     DOI: 10.1128/JCM.40.8.2828-2831.2002
Copyright © 2002, American Society for Microbiology. All Rights Reserved.



This article has been cited by other articles:


This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Hahn, R. C.
Right arrow Articles by Hamdan, J. S.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Hahn, R. C.
Right arrow Articles by Hamdan, J. S.

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
Antimicrob. Agents Chemother. Clin. Microbiol. Rev.
Clin. Vaccine Immunol. ALL ASM JOURNALS